LIDDS AB (LIDDS) AI Stock Analysis

• Market Cap: kr3.14M
• Dividend Yield: N/A
• Average Volume (3M): 48.19K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.39
• Revenue Growth: N/A
• EPS Growth: 86.26%
• Country: SE
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 136,463,330
• 10 Day Avg. Volume: 51,372
• 30 Day Avg. Volume: 48,191
• PEG Ratio: 0.03
• Price to Book (P/B): 2.24
• Price to Sales (P/S): 432.85
• P/FCF Ratio: -2.51
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: kr0.02 ▼(-45.00% Downside)

The score is driven primarily by weak financial performance (near-zero revenue, ongoing losses and cash burn, and a reduced equity cushion), reinforced by bearish technical signals (below major moving averages and negative MACD). Valuation provides limited support because the negative P/E reflects unprofitability and no dividend yield is available.

Positive Factors

Platform technology (NanoZolid®)

A proprietary delivery platform that enables sustained local drug release is a durable competitive asset. NanoZolid® can be applied across indications and compounds, supporting repeatable licensing, co-development deals or royalties, which underpins long-term franchise value beyond any single asset.

Low financial leverage (no debt)

A zero-debt balance sheet materially lowers short- and medium-term solvency risk for a development-stage biotech. With no scheduled interest or principal obligations, management has more flexibility to prioritize R&D timelines, pursue partnerships, and time financings without immediate debt service constraints.

Improving cash burn trend

A sustained reduction in cash burn versus prior years indicates improved operational discipline and extends runway between financings. For a pre-commercial company this reduces dilution risk frequency and improves odds of completing key development milestones before new capital is required.

Negative Factors

Near-zero revenue, pre-commercial profile

Minimal product or licensing revenue means the company remains dependent on external funding or milestone deals to finance operations. Lack of material revenue limits ability to self-fund development and increases execution risk if partner deals or capital markets access tighten over months.

Persistent losses and negative cash flow

Ongoing operating losses and negative free cash flow erode equity and force repeated financing or dilutive partnerships. Over the medium term this constrains spending on clinical programs, heightens refinancing risk, and can weaken negotiating leverage with potential partners or acquirers.

Shrinking equity cushion

A materially contracted equity base reduces the company’s ability to absorb trial setbacks, delays, or unexpected costs. With a thin capital buffer management faces tighter timelines to secure financing or partnerships, which can force less favorable deal terms and increase long-term execution risk.

LIDDS AB Business Overview & Revenue Model

Company Description

LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden. It is developing various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX to treat breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX for the treatment of solid tumors; NZ-IO, an immunotherapy; NZ-STING for the treatment of immuno-oncology; and NZ-TLR9 for enhancing cancer immunotherapies. LIDDS AB (publ) has a collaboration agreement with PharmIdea SIA to focus on anti-cancer drugs and sterile formulations. The company is based in Uppsala, Sweden.

How the Company Makes Money

LIDDS AB generates revenue through licensing agreements, collaborations, and partnerships with pharmaceutical companies interested in utilizing its NanoZolid® technology for their drug development projects. The company earns upfront payments, milestone payments, and royalties based on the commercial success of products developed using their technology. Additionally, LIDDS might engage in contract research and development services, offering its expertise in drug formulation and delivery. These strategic alliances and service offerings are crucial for the company's financial performance and growth in the competitive pharmaceutical industry.

LIDDS AB Financial Statement Overview

Summary

LIDDS AB faces significant challenges across its financial statements. The income statement reflects ongoing operational and profitability issues, while the balance sheet remains debt-free but fails to translate into positive returns. Cash flow pressures persist, with negative free cash flow indicating liquidity challenges. The company needs to focus on improving its revenue growth and operational efficiency to enhance its financial health.

Income Statement

LIDDS AB has struggled with consistently negative gross and net profit margins over multiple years, indicating ongoing profitability challenges. The revenue growth rate was positive for 2024 due to a very low base in 2023, but overall, the company has not shown sustainable revenue growth. EBIT and EBITDA margins are also negative, further highlighting operational inefficiencies.

Balance Sheet

The company has a strong equity position with no debt, leading to a solid equity ratio. However, the return on equity is negative due to persistent losses, which is a concern. The balance sheet shows stability in terms of equity but highlights the challenge of translating this into profitability.

Cash Flow

Free cash flow remains negative, although the company has managed to reduce its cash flow deficit over the years. The operating cash flow to net income ratio is negative, reflecting cash outflows exceeding net losses. The company has not been able to generate positive free cash flow consistently, which limits its financial flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	32.00K	0.00	1.89M	3.55M	345.00K
Gross Profit	-2.77M	-3.40M	-12.92M	-36.62M	-25.78M	-24.79M
EBITDA	-4.06M	-4.49M	-39.67M	-36.11M	-36.81M	-32.20M
Net Income	-3.95M	-5.94M	-40.21M	-36.86M	-37.27M	-32.33M
Balance Sheet
Total Assets	1.98M	8.16M	17.66M	25.92M	55.58M	54.20M
Cash, Cash Equivalents and Short-Term Investments	1.73M	5.51M	13.51M	5.26M	34.00M	36.07M
Total Debt	0.00	0.00	0.00	3.99M	0.00	0.00
Total Liabilities	491.00K	1.98M	3.76M	10.57M	7.07M	11.40M
Stockholders Equity	1.49M	6.18M	13.90M	15.35M	48.51M	42.81M
Cash Flow
Free Cash Flow	-3.99M	-5.53M	-26.50M	-36.40M	-45.04M	-31.17M
Operating Cash Flow	-3.93M	-5.43M	-26.22M	-35.59M	-42.64M	-27.42M
Investing Cash Flow	-63.00K	11.03M	-282.00K	-810.00K	-2.40M	-3.75M
Financing Cash Flow	-824.00K	-280.00K	34.76M	7.66M	42.97M	59.64M

LIDDS AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:LIDDS, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.05, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 28.56 is Positive, neither overbought nor oversold. The STOCH value of 6.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:LIDDS.

LIDDS AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FLUI	46 Neutral	kr14.42M	-1.48	-45.97%	―	―	―
LARK	43 Neutral	kr46.14M	-1.00	―	8.47%	-94.12%	-25.83%
LIDDS	42 Neutral	kr3.14M	-0.34	-132.58%	―	―	86.26%
STABL	42 Neutral	kr15.67M	-1.34	-91.33%	―	―	64.02%